Assessing the Risk for Gout With SGLT2 Inhibitors in Patients With Diabetes – Annals of Internal Medicine

Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, and Sinai Health System and University of Toronto, Toronto, Ontario, Canada (M.F.)

Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (S.K.C., E.P., S.C.K.)

Financial Support: By the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School. Dr. Fralick received funding from the Eliot Phillipson Clinician-Scientist Training Program at the University of Toronto and the Canadian Institutes of Health Research through the Banting and Best PhD Award. Dr. Patorno is supported by a career development grant (K08AG055670) from the National Institute on Aging.

Disclosures: Dr. Patorno reports grants from the National Institute on Aging and Boehringer Ingelheim outside the submitted work. Dr. Kim reports grants from Pfizer, AbbVie, Roche, and Bristol-Myers Squibb outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at http://www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-2610.

Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose.

Reproducible Research Statement:Study protocol: Available from Dr. Fralick (e-mail, mike.fralick@mail.utoronto.ca). Statistical code: Not available. Data set: Available through IBM MarketScan (e-mail, watsonh@us.ibm.com).

Corresponding Author: Michael Fralick, MD, PhD, SM, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120; e-mail, mike.fralick@mail.utoronto.ca.

Current Author Addresses: Drs. Fralick, Chen, Patorno, and Kim: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120.

Author Contributions: Conception and design: M. Fralick, S.K. Chen, E. Patorno, S.C. Kim.

Analysis and interpretation of the data: M. Fralick, S.K. Chen, S.C. Kim.

Drafting of the article: M. Fralick, S.K. Chen.

Critical revision for important intellectual content: M. Fralick, S.K. Chen, E. Patorno, S.C. Kim.

Final approval of the article: M. Fralick, S.K. Chen, E. Patorno, S.C. Kim.

Statistical expertise: S.C. Kim.

Administrative, technical, or logistic support: M. Fralick, S.C. Kim.

Collection and assembly of data: M. Fralick.

Read the original:
Assessing the Risk for Gout With SGLT2 Inhibitors in Patients With Diabetes - Annals of Internal Medicine